Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process.
about
Validation of Transient Elastography and Comparison with Spleen Length Measurement for Staging of Fibrosis and Clinical Prognosis in Primary Sclerosing Cholangitis.Investigating the safety and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTEO): A single-arm, two-stage, open-label, multi-centre, phase II clinical trial protocol.Does transient elastography correlate with liver fibrosis in patients with PSC? Laennec score-based analysis of explanted livers.Emerging treatments for primary sclerosing cholangitis.Emerging pharmacologic therapies for primary sclerosing cholangitis.Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis.Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study.Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study.Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: evaluation of prognostic value.New therapies target the toxic consequences of cholestatic liver disease.Primary sclerosing cholangitis and the management of uncertainty and complexity.Novel Bile Acid Therapies for Liver Disease.Association of gadolinium-enhanced magnetic resonance imaging with hepatic fibrosis and inflammation in primary sclerosing cholangitis.Using a meta-narrative literature review and focus groups with key stakeholders to identify perceived challenges and solutions for generating robust evidence on the effectiveness of treatments for rare diseases.Primary Sclerosing Cholangitis, Part 1: Epidemiology, Etiopathogenesis, Clinical Features, and Treatment.Primary Sclerosing Cholangitis
P2860
Q36159366-089CED03-3D90-4454-B465-1130AF44E44DQ38374581-5E3E0CF6-1C84-4CD0-987A-FB0BAFAEF2C4Q38603479-FEEF7FB4-DDE1-41BE-8E2F-90A4B6169310Q38748384-A3F93B08-60FB-45A0-94FF-EEBA2CE4FB83Q38751076-C5C3C86C-61B1-407C-BFD3-AF6661263F6BQ38833243-35BA4328-590A-4ABC-BDDE-AFB651BC44CAQ38924675-8D77FA06-EC33-4DEA-9B3D-2404F65B8B1AQ40460115-E81EBD30-5635-4C84-9E42-A019420AEF02Q40870367-D3622AFD-7E33-46E4-8F33-052C390C70B9Q47223909-EC86F7B8-861C-4D37-A4FB-80FAD779BB6DQ50079121-895390B7-AD70-45FF-B7AC-E15FA8F6E28AQ52614648-C37B5C12-FA3E-4A08-A970-A884D745A250Q55188628-3FE7F7E4-7E33-470A-9A58-6ABF3D7E3187Q55457221-D5C959B6-4F9C-40B8-A41E-9D970B047BA8Q55497458-B6F87A5E-B809-45A5-874D-FF6D1E600650Q56442935-A556E2CE-C815-4095-8CB7-624E4E5C4E2A
P2860
Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Surrogate endpoints for clinic ...... Study Group consensus process.
@en
type
label
Surrogate endpoints for clinic ...... Study Group consensus process.
@en
prefLabel
Surrogate endpoints for clinic ...... Study Group consensus process.
@en
P2093
P2860
P356
P1433
P1476
Surrogate endpoints for clinic ...... Study Group consensus process.
@en
P2093
Ansgar W Lohse
Cyriel Y Ponsioen
Erik Schrumpf
Massimo Pinzani
Michael Trauner
Olivier Chazouillères
Roger W Chapman
Tom H Karlsen
P2860
P304
P356
10.1002/HEP.28256
P407
P577
2015-09-29T00:00:00Z